Evidence map›Paper›PMID 29153199›Full record

ReviewHeart failure clinics2018

Soluble ST2 in Heart Failure.

Cian P McCarthy, James L Januzzi

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure clinics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05335629 (Evaluation of the Effect of Dapagliflozin on Cardiac Remodeling in Post Myocardial Infarction Patients), which is not on this map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05335629 nacompletedstarted 2022, after this paper: background citation

Evaluation of the Effect of Dapagliflozin on Cardiac Remodeling in Post Myocardial Infarction Patients

Ran2022Enrolled54Registered outcomes2Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Myocardial Infarction, Myocardial Remodeling, VentricularArmsDapagliflozin 10mg Tab
PMID 15226248PMID 16286016PMID 17492053PMID 28450225PMID 29285671PMID 29922732PMID 30416379PMID 30710997PMID 32578850PMID 30999996PMID 32626540PMID 31182683other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Cian P McCarthyDepartment of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
James L JanuzziDivision of Cardiology, Department of Medicine, Massachusetts General Hospital, 32 Fruit Street, Yawkey 5984, Boston, MA 02114, USA; Baim Institute for Clinical Research, Cardiometabolic Trials, 930 Commonwealth Avenue, Boston, MA 02115, USA. Electronic address: jjanuzzi@partners.org.
Baim Institute for Clinical Research · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suppression of tumorigenicity 2 (ST2) is a member of the interleukin (IL)-1 receptor family, whose role was originally established in the context of inflammatory and autoimmune diseases. More recently, testing for ST2 has been used in the setting of cardiovascular disease. The soluble form of ST2 is a decoy receptor that inhibits beneficial cardioprotective effects of IL-33; such inhibition results in cardiac hypertrophy, myocardial fibrosis, and ventricular dysfunction. Measurement of soluble ST2 has utility for assessing heart failure severity and prognosis. In this review, we examine the role of soluble ST2 in both acute and chronic heart failure.

Indexed as

BiomarkersHeart FailureHumansInterleukin-1 Receptor-Like 1 ProteinPrognosisReceptors, Interleukin-1BiomarkersIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinReceptors, Interleukin-1Heart failureNovel cardiac biomarkersPrognosisRisk stratificationST2

Identifiers

PMID29153199
OpenAlexW2770304328

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.